Mise en page

ORAL COMMUNICATIONS
SUNDAY, 8 JULY 2007
15:45 - 17:15
INDUCTION OF FACTOR VIII SPECIFIC UNRESPONSIVENESS BY
INTRATHYMIC FACTOR VIII INJECTION IN MURINE HEMOPHILIA A
S. Madoiwa* (JP), T. Yamauchi, E. Kobayashi, Y. Hakamata,
T. Ohmori, J. Mimuro, Y. Sakata
THE RISK OF INHIBITOR DEVELOPMENT IN 1104 PATIENTS WITH
HEMOPHILIA A ACCORDING TO FACTOR VIII GENOTYPE
J. Boekhorst* (NL), G. Rastegar Lari, R. D'Oiron, J. M. Costa,
I. R. O. Novakova, F. A. Ala, J. M. Lavergne, W. L. Van Heerde
NEUTRALIZING ANTI-FVIII ANTIBODIES HAVE A DIFFERENT IMPACT IN
INHIBITING THROMBIN GENERATION
Y. Dargaud* (FR), J. Healey, P. Lollar, J. Plantier, C. Négrier
ASSOCIATION BETWEEN A HISTORY OF INHIBITORS AND DELAYS IN
SKELETAL MATURATION IN ADOLESCENTS WITH HEMOPHILIA
S. M. Donfield* (US), A. E. Lail, E. D. Gomperts, W. Hoots,
E. Berntorp, H. S. Lynn
Hormones, pregnancy, women’s issues I
Chairpersons: F. Boehlen (CH), M. A. Rodger (CA) IMPACT OF RISK FACTORS ASSOCIATED WITH VENOUS THROMBOSIS IN
CYPROTERONE ACETATE AND ETHYNIL-ESTRADIOL USERS OR OTHER
ORAL CONTRACEPTIVES USERS AND POSSIBLY PREVENTABLE CASES
J. Conard* (FR), G. Plu-Bureau, K. Adida, M. Horellou
DIFFERENTIAL EFFECTS OF TRANSDERMAL AND ORAL ESTRADIOL /
NORETHISTERONE ACETATE HORMONE THERAPIES ON COAGULATION
AND FIBRINOLYTIC MARKERS
J. F. Brosnan* (IE), B. L. Sheppard, L. A. Norris
SNPS NEAR THE ESTROGEN SULFOTRANSFERASE GENE SULT1E1 AND
THE RISK OF VENOUS THROMBOSIS IN RELATION TO ORAL
CONTRACEPTIVE USE
H. L. Vos* (NL), A. Van Hylckama Vlieg, F. R. Rosendaal
THE RISK OF PREGNANCY-RELATED VENOUS THROMBOEMBOLISM IN
DOUBLE CARRIERS OF FACTOR V LEIDEN AND PROTHROMBIN G20210A
T. Battaglioli* (IT), V. De Stefano, D. Tormene, L. Valdré, E. Grandone,
A. Tosetto, I. Martinelli
INHERITED THROMBOPHILIA AND PREECLAMPSIA WITHIN A COHORT OF
5337 WOMEN: RESULTS OF THE MONTREAL PREECLAMPSIA STUDY
S. R. Kahn* (CA), R. Platt, H. McNamara, M. Kramer
ORAL COMMUNICATIONS
SUNDAY, 8 JULY 2007
15:45 - 17:15
FACTOR V LEIDEN (FVL) AND PROTHROMBIN GENE VARIANT (PGV) MAY
BE ONLY WEAKLY ASSOCIATED WITH PLACENTA MEDIATED PREGNANCY
COMPLICATIONS: A LARGE PROSPECTIVE COHORT STUDY
Sunday Or
M. A. Rodger* (CA), M. C. Walker, N. Carson, B. Gin, P. S. Wells, S. Wu Wen, G. Smith Heparin-induced thrombocytopenia
Chairpersons: M. Poncz (US), T. E. Warkentin (CA) THERAPEUTIC ANTIBODIES AGAINST CD40 LIGAND,
TNF-ALPHA AND VEGF SHARE MECHANISTIC FEATURES IN COMMON
WITH PLATELET ACTIVATING ANTIBODIES IN HEPARIN-INDUCED
THROMBOCYTOPENIA (HIT)
M. Davila* (US), T. Meyer, F. Langer, T. Robson, L. Robles,
H. Desai, A. Amirkhosravi, M. Amaya, P. Elias, J. Francis
THE ROLE OF HIT PLATELET FACTOR 4 ANTIGENIC COMPLEXES ON
MONOCYTE SURFACES IN THE PATHOGENESIS OF HEPARIN-INDUCED
THROMBOCYTOPENIA
L. Rauova* (US), D. B. Cines, M. Poncz
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) AND DILATED
CARDIOMYOPATHY (DCM) - PARALLELS IN THE PATHOGENESIS OF TWO
SEVERE IMMUNE MEDIATED CARDIOVASCULARE DISORDERS
A. Greinacher* (DE), A. Staudt, P. Eichler, C. Trimpert, S. Felix
EVALUATION OF A PRE-TEST CLINICAL SCORE FOR THE DIAGNOSIS OF
HIT
S. J. McRae* (AU), M. Al Muslahi, E. M. Duncan, R. Tadros,
J. V. Lloyd, T. E. Warkentin
HEPARIN INDEPENDENT ACTIVATION OF PLATELETS BY HIT ANTIBODIES.
A COMMON OCCURRENCE
I. Socher* (DE), H. Kroll, U. Sachs
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT): A PROSPECTIVE STUDY
ON THE INCIDENCE, PLATELET-ACTIVATING CAPACITY AND CLINICAL
SIGNIFICANCE OF ANTI-PLATELET FACTOR 4/HEPARIN ANTIBODIES
(ANTI-PF4/H ABS) OF THE IGG, IGM, AND IGA CLASS
A. Greinacher* (DE), T. E. Warkentin, U. Strobel, R. Raschke,
B. Fuerll, A. Wessel, N. Lubenow, P. Eichler, D. Juhl

Source: http://www.isth2009.com/isth2007/final/Hormones_pregnancy_Room_C_Sunday_15_45.pdf